ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,765 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselNBE-Therapeutics AG
NBE-Therapeutics AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of NBE-Therapeutics AG is the development and research of therapeutics, particularly in the field of cancer treatment. The company focuses on the development of antibody-drug conjugates (ADCs) and other therapeutics targeting the fight against cancer cells.

AI-generated
Offering

Products & services

LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

NBE-Therapeutics AG

Industry:Research & DevelopmentPharmaceutical Industry
✓ Offered7
Oncology treatments
Oncology treatments based on next-generation antibody-drug conjugates, developed to target solid tumors and improve survival and quality of life for cancer patients.
Antibody-drug conjugate technology
Antibody-drug conjugate platform combining monoclonal antibodies with small-molecule payloads, including tailored design of antibody, payload, DAR, conjugation site and homogeneity.
Site-specific conjugation
Enzymatic site-specific antibody conjugation with sortaseA transpeptidase, described as SMAC technology for antibody conjugation.
PNU anthracycline payload
Anthracycline-based payload for ADCs, described as a highly potent DNA-damaging intercalating toxin with picomolar potency.
Antibody discovery
Discovery of novel binders against new targets using a mammalian antibody library display system.
Immune-oncology function of anthracyclines
Immune-oncology activity of anthracyclines, described as stimulating dendritic cells and adaptive cellular immunity.
Partnerships and collaboration
Partnerships and collaboration for advancing cancer-care programs, including contact for collaboration and references to existing partner relationships.
Trust & reputation

ranQ Trust Score of NBE-Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

NBE-Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
NBE-Therapeutics AG scores 91.3 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.97.712%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
NBE-Therapeutics AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
NBE-Therapeutics AG scores 60.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.20.04%
Qualifications+0.00

NBE-Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

October 5, 2020Media
Startups win strong and well-connected board members
startupticker.ch
October 29, 2019Media
Biotech startups strengthen their teams
startupticker.ch

Knowledge

No knowledge articles yet

Once NBE-Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

NBE-Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank NBE-Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of NBE-Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hochbergerstrasse 60i
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-153.827.725
Founded
2012 · 14 years
Last commercial register change
July 10, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    BA
    BioVersys AG
    Basel
    CT
    ClearideBio Therapeutics AG
    Basel
    LT
    LifeMine Therapeutics (Switzerland) GmbH
    Basel
    NP
    Nxera Pharma CH Services GmbH
    Basel
    SB
    SOTIO Biotech AG
    Basel
    SA
    Scailyte AG
    Basel
    CT
    CORETAG Therapeutics AG
    Basel
    AG
    AlphaMeld GmbH
    Basel